Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Van Osselaer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2003
Assays for chemotaxisAnja Wuyts, Patricia Menten, Nancy Van Osselaer, et al.
Epilepsy & Behavior : E&B|December 18, 2017
A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programsEdward Atkinson-Clark, Mata Charokopou, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|May 20, 2003
Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulationsVladimir Piotrovsky, Achiel Van Peer, Nancy Van Osselaer, et al.
Biopharmaceutics & Drug Disposition|March 3, 2012
From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case exampleVikash Kumar Sinha, Jan Snoeys, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|September 5, 2002
Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjectsQinying Zhao, Martin Brett, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|August 29, 2009
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseSandra Boom, Krishna Talluri, Luc Janssens, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2008
Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humansMarc Vermeir, Ineke Naessens, Bart Remmerie, et al.
Epilepsia|January 24, 2018
Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) modelCameron S Metcalf, Brian D Klein, Misty D Smith, et al.
Epilepsia|February 7, 2017
Efficacy of mGlu<sub>2</sub> -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizuresCameron S Metcalf, Brian D Klein, Misty D Smith, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2003
Assays for chemotaxisAnja Wuyts, Patricia Menten, Nancy Van Osselaer, et al.
Epilepsy & Behavior : E&B|December 18, 2017
A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programsEdward Atkinson-Clark, Mata Charokopou, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|May 20, 2003
Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulationsVladimir Piotrovsky, Achiel Van Peer, Nancy Van Osselaer, et al.
Biopharmaceutics & Drug Disposition|March 3, 2012
From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case exampleVikash Kumar Sinha, Jan Snoeys, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|September 5, 2002
Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjectsQinying Zhao, Martin Brett, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|August 29, 2009
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseSandra Boom, Krishna Talluri, Luc Janssens, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2008
Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humansMarc Vermeir, Ineke Naessens, Bart Remmerie, et al.
Epilepsia|January 24, 2018
Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) modelCameron S Metcalf, Brian D Klein, Misty D Smith, et al.
Epilepsia|February 7, 2017
Efficacy of mGlu<sub>2</sub> -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizuresCameron S Metcalf, Brian D Klein, Misty D Smith, et al.
Pageof 2